ProMIS Neurosciences (PMN) Cash from Operations (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Cash from Operations came in at 12383520.0 in Q1 2026, down 151.35% YoY from 24117413.65 in Q1 2025, and down 33.42% on a QoQ basis from 9281906.0 in Q4 2025.
ProMIS Neurosciences (PMN) Cash from Operations (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 6 years of Cash from Operations data on file, last reported at 12383520.0 in Q1 2026.
- Quarterly Cash from Operations fell 151.35% year-over-year to 12383520.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35575233.0 (down 63.06% YoY) and the FY2025 annual result came in at 28118579.0, down 3.45% from the prior year.
- Cash from Operations fell to 12383520.0 in Q1 2026, from 9281906.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 1504510.0 in Q2 2024 to a low of 12383520.0 in Q1 2026.
- A 5-year average of 5621279.59 and a median of 4553628.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations sank 301.75% — and 2025, when it surged 52.13%.
- Tracing PMN's Cash from Operations over 5 years: stood at 4553628.0 in 2022, then increased by 17.47% to 3758238.0 in 2023, then slumped by 131.89% to 8715037.0 in 2024, then decreased by 6.5% to 9281906.0 in 2025, then tumbled by 33.42% to 12383520.0 in 2026.
- The last three Cash from Operations figures came in at 12383520.0 (Q1 2026), 9281906.0 (Q4 2025), and 10055625.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.60 Bn | 130.75 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.93 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.06 Bn | 59.88 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.22 Bn | 51.08 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.65 Bn | 28.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.31 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | 728.46 Mn |
| 10 | ProMIS Neurosciences | 135.44 Mn | 81.98 Mn | - | -10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.40 Mn |
| Jun 30, 2026 | -10.40 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Mar 31, 2026 | -12.38 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Sep 30, 2025 | -10.06 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Jun 30, 2025 | -3.85 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Mar 31, 2025 | -4.93 Mn |
| Dec 31, 2024 | -8.72 Mn |
| Dec 31, 2024 | -8.72 Mn |
| Sep 30, 2024 | -6.67 Mn |
| Sep 30, 2024 | -6.67 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Jun 30, 2024 | -1.50 Mn |
| Mar 31, 2024 | -10.29 Mn |
| Mar 31, 2024 | -10.29 Mn |